Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.

ABSTRACT:

Background and aims

Chronic HEV infections remain a serious problem in immunocompromised patients, as specifically approved antiviral drugs are unavailable. In 2020, a 24-week multicenter phase II pilot trial was carried out, evaluating the nucleotide analog sofosbuvir by treating nine chronically HEV-infected patients with sofosbuvir (Trial Number NCT03282474). During the study, antiviral therapy reduced virus RNA levels initially but did not lead to a sustained virologic response. Here, we characterize the changes in HEV intrahost populations during sofosbuvir treatment to identify the emergence of treatment-associated variants.

Approach and results

We performed high-throughput sequencing on RNA-dependent RNA polymerase sequences to characterize viral population dynamics i

SUBMITTER: Gomer A 

PROVIDER: S-EPMC10653298 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature